GR1004331B - Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος - Google Patents

Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος

Info

Publication number
GR1004331B
GR1004331B GR20020100436A GR20020100436A GR1004331B GR 1004331 B GR1004331 B GR 1004331B GR 20020100436 A GR20020100436 A GR 20020100436A GR 20020100436 A GR20020100436 A GR 20020100436A GR 1004331 B GR1004331 B GR 1004331B
Authority
GR
Greece
Prior art keywords
pharmaceutical compositions
contain
alendronic acid
salt
new pharmaceutical
Prior art date
Application number
GR20020100436A
Other languages
English (en)
Inventor
Μυρσινη Πανταζοπουλου
Original Assignee
Verisfield (Uk) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verisfield (Uk) Ltd filed Critical Verisfield (Uk) Ltd
Priority to GR20020100436A priority Critical patent/GR1004331B/el
Publication of GR1004331B publication Critical patent/GR1004331B/el
Priority to EP20030386023 priority patent/EP1407766B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

έες φαρμακευτικές συνθέσεις που περιέχουν σαν δραστικό συστατικό το Αλενδρονικό οξύ υπό τη μορφή αλάτων του σε υδρική μορφή σε συγκεκριμένο συνδυασμό με έκδοχα και την χρήση της μαννιτόλης ως αραιωτικού μέσου.Οι εν λόγω φαρμακευτικές συνθέσεις θα παρασκευάζονται με νέο τρόπο παραγωγής χρησιμοποιώντας νέους φορείς. Οι φαρμακοτεχνικές μορφές που περιγράφονται είναι κάψουλες, δισκία καθώς και κοκκία ή κόνεις για παρασκευή ποσίμων εναιωρημάτων σε διάφορες περιεκτικότητες. Οι εν λόγω φαρμακοτεχνικές μορφές παρασκευάζονται με υγρή κοκκοποίηση του μίγματος των εκδόχων με τη χρήση ύδατος. Οι παραπάνω φαρμακευτικές συνθέσεις χρησιμοποιούνται για την καταπολέμηση και την πρόληψη της οστεοπόρωσης. ΰ
GR20020100436A 2002-10-07 2002-10-07 Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος GR1004331B (el)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GR20020100436A GR1004331B (el) 2002-10-07 2002-10-07 Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
EP20030386023 EP1407766B1 (en) 2002-10-07 2003-10-03 Pharmaceutical compositions that contain a salt of alendronic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20020100436A GR1004331B (el) 2002-10-07 2002-10-07 Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος

Publications (1)

Publication Number Publication Date
GR1004331B true GR1004331B (el) 2003-09-05

Family

ID=29559940

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20020100436A GR1004331B (el) 2002-10-07 2002-10-07 Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος

Country Status (2)

Country Link
EP (1) EP1407766B1 (el)
GR (1) GR1004331B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046100A1 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Pharmaceutical composition of alendronic acid
NL1027807C1 (nl) * 2004-12-17 2006-06-20 4Sight Innovation Bv Inrichting voor het verrijken van een drank met additieven, en verpakking voor een dergelijke inrichting.
WO2008020305A2 (en) * 2006-08-17 2008-02-21 Aurobindo Pharma Limited Solid dosage forms of bisphosphonic acids

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
WO2001085176A1 (en) * 2000-05-11 2001-11-15 Instytut Farmaceutyczny The solid oral pharmaceutical composition comprising a bisphosphonic acid derivative
WO2002003963A1 (en) * 2000-07-11 2002-01-17 Léciva A.S. Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid as active ingredient

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
WO2001085176A1 (en) * 2000-05-11 2001-11-15 Instytut Farmaceutyczny The solid oral pharmaceutical composition comprising a bisphosphonic acid derivative
WO2002003963A1 (en) * 2000-07-11 2002-01-17 Léciva A.S. Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid as active ingredient

Also Published As

Publication number Publication date
EP1407766A3 (en) 2004-04-28
EP1407766B1 (en) 2009-07-01
EP1407766A2 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
WO2007146248A3 (en) Stable laquinimod preparations
CA2481848A1 (en) Active ingredient particles carrying clopidogrel or a salt thereof, their use and method of preparation
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
MXPA04003636A (es) Composiciones farmaceuticas que comprenden acido micofenolico o sal de micofenolato.
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
MXPA03001169A (es) Biciclo-pirazoles activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos.
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2012022919A3 (fr) Formulations à base de nalbuphine et leurs utilisations
WO2004078105A3 (fr) Composition de fondaparinux sodique de haute purete
WO2007021970A3 (en) Stable pharmaceutical formulations and methods of use thereof
HK1203815A1 (en) Pharmaceutical compositions and methods for their preparation
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
WO2007100382A3 (en) Orally administrable gallium compositions and method of use
WO2004098594A3 (en) Dosage form containing pantoprazole as active ingredient
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
GB2443793B (en) Product, method of manufacture and use
WO2006072070A3 (en) Pharmaceutical formulations of gallium salts
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
SI1954251T1 (sl) Sestavek s počasnim sproščanjem, ki ima kot aktivno učinkovino Fe sol, postopek njegove priprave in uporabe
GR1004331B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
WO2006127319A3 (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same

Legal Events

Date Code Title Description
PG Patent granted
ML Lapse due to non-payment of fees

Effective date: 20160506